BR1015
Sponsors
Boryung Pharmaceutical Co., Ltd
Conditions
Essential HypertensionHypertension
Phase 1
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fed Conditions in Healthy Volunteers
CompletedNCT06008015
Start: 2023-09-04End: 2023-10-03Updated: 2023-10-31
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions in Healthy Volunteers
CompletedNCT06008028
Start: 2023-08-10End: 2023-10-06Updated: 2023-11-18
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers Fed Conditions
CompletedNCT06744062
Start: 2025-01-05End: 2025-03-19Updated: 2025-04-09
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions
CompletedNCT06744127
Start: 2025-01-03End: 2025-03-14Updated: 2025-04-09
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions
CompletedNCT06744439
Start: 2025-01-09End: 2025-03-16Updated: 2025-04-09
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions
CompletedNCT06744426
Start: 2025-01-04End: 2025-03-12Updated: 2025-04-09